2 results
Approved WMOCompleted
Primary:To evaluate if progression-free survival from randomization to progression or death during second-line therapy (total PFS) of sorafenib followed by pazopanib is non-inferior compared to pazopanib followed by sorafenib.Secondary:1. Time from…
Approved WMOCompleted
To determine whether a potent topical CS is more effective than a mild topical CS in the treatment of children with a moderate flare-up of atopic dermatitis in primary care on short and long term.